LSG vs MGB-OAGB—3 Year Follow-up Data: a Randomised Control Trial

Apr 22, 2018Obesity surgery

Three-Year Comparison of LSG and MGB-OAGB Weight-Loss Surgeries in a Randomized Trial

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

After 3 years, the average percentage of excess weight loss (%EWL) was 66.48% for MGB-OAGB and 61.15% for LSG, with no statistically significant difference.

Diabetes remission occurred in 89.13% of MGB-OAGB patients compared to 81.82% of LSG patients.
Hypertension remission was observed in 74% of MGB-OAGB patients, while 72.22% of LSG patients achieved remission.
Quality of life, measured by the BAROS score, was higher in MGB-OAGB patients with comorbidities (6.96) compared to LSG patients (6.03).
In patients without comorbidities, the BAROS score was 4.34 for MGB-OAGB and 3.86 for LSG.

AI simplified

AIM: The objective of this study is to compare 3-year follow-up results of one anastomosis gastric bypass (MGB-OAGB) and laparoscopic sleeve gastrectomy (LSG) in terms of weight loss, complications, resolution of comorbidities and quality of life.

MATERIALS AND METHODS: A prospective randomised study of results between 100 LSG patients and 101 MGB-OAGB patients was done from 2012 to 2015. The results were compared regarding operative outcomes, percentage of excess weight loss (%EWL), complications, resolution of comorbidities and quality of life (BAROS score) at 3 years follow-up.

RESULTS: Follow-up was achieved in 93 MGB-OAGB vs 92 LSG patients for 3-year period. The average %EWL for MGB-OAGB vs LSG was 66.48 vs 61.15% at the end of 3 years respectively, which was statistically insignificant. Diabetes remission was seen in 89.13% of MGB-OAGB patients and 81.82% of LSG patients. Remission of hypertension was seen in 74% of MGB-OAGB patients and 72.22% of LSG patients. Bariatric analysis reporting and outcome system (BAROS) with comorbidity in LSG patients and MGB-OAGB patients was 6.03 and 6.96 respectively, whereas in patients without comorbidity, BAROS score was 3.86 in LSG group and 4.34 in MGB-OAGB group.

CONCLUSIONS: In our study, at 36 months follow up, there was no significant difference between LSG and MGB-OAGB in %EWL and remission of HTN. Type 2 diabetes mellitus (T2DM) remission rates were higher after MGB-OAGB as compared to LSG but the difference was statistically insignificant. MGB-OAGB patients with comorbidities have a better quality of life and BAROS score compared to LSG patients.

Full Text

Full text is available at the source.

View full text (HTML) ↗View full text (PDF) ↗

LSG vs MGB-OAGB—3 Year Follow-up Data: a Randomised Control Trial

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief